Fate Therapeutics, Inc.
FATENASDAQHealthcare● Active
$1.99
+$0.08(+4.19%)
Market Cap$231952410
P/E Ratio—
52W High$2.88
52W Low$0.91
Fate Therapeutics, Inc. (FATE) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · FATE · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($136.31M) | ($186.26M) | ($160.93M) | ($281.72M) | ($212.15M) |
| Depreciation & Amort. | $9.29M | $18.96M | $18.28M | $13.76M | $5.85M |
| Stock-Based Comp. | $24.92M | $41.50M | $43.46M | $78.73M | $54.36M |
| Change in Working Capital | ($3.74M) | ($1.96M) | $19.18M | ($34.71M) | $2.10M |
| Net Cash from Operations | ($106.08M) | ($122.87M) | ($132.26M) | ($248.21M) | ($162.87M) |
| Investing Activities | |||||
| Capital Expenditure | ($5.95M) | ($0.73M) | ($6.15M) | ($35.57M) | ($50.70M) |
| Purchases of Investments | ($195.14M) | ($317.75M) | ($358.81M) | ($404.80M) | ($968.16M) |
| Sales of Investments | $311.90M | $330.70M | $477.63M | $607.11M | $694.84M |
| Net Cash from Investing | $111.17M | $12.22M | $112.67M | $166.75M | ($324.02M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Financing | $5.49M | $99.89M | $0.09M | $9.21M | $453.13M |
| Free Cash Flow | |||||
| Free Cash Flow | ($112.04M) | ($123.60M) | ($138.42M) | ($283.77M) | ($213.57M) |
| FCF Margin %(computed) | — | -906.79% | -217.86% | -294.68% | -382.43% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Fate Therapeutics, Inc. data
About Fate Therapeutics, Inc. (FATE) Cash Flow Statement
Fate Therapeutics, Inc. generated operating cash flow of ($0.11B) and free cash flow of ($0.11B) for 2025 — a FCF margin of -1685.78%. Capital expenditure was ($0.01B).
Frequently asked questions
FATE · 4 questionsFate Therapeutics, Inc. generated free cash flow of ($0.11B) for 2025, up 9.4% year-over-year.
FATE free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10